Companies: Hikma Pharmaceuticals, Amarin
Generic Drugmakers Gain Key Victory in ‘Skinny Label’ Patent Case
100% citation coverage1 peer-reviewed sources
The US Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents in a skinny-label case, overturning a lower court decision. This decision makes generic drugmakers less vulnerable to lawsuits over skinny labels, preserving a key pathway for early market entry on unpatented indications.
Executive Summary
- The Supreme Court sided with Hikma in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. , reversing a lower court that had found Hikma liable for inducing patent infringement based on its marketing statements.
- The ruling removes a major legal threat for generic companies using skinny labels to launch on unpatented indications, reducing the risk of costly damages and automatic 30-month litigation stays.
- Brand-name drugmakers may face accelerated generic competition for multi-indication drugs, while legal and commercial teams should reassess labeling and launch strategies in light of the Court's reasoning.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Generic Drugmakers Gain Key Victory in 'Skinny Label' Patent Case
The US Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents in a skinny-label case, overturning a lower court decision. This decision makes generic drugmakers less vulnerable to lawsuits over skinny labels, preserving a key pathway for early market entry on unpatented indications.
Key Takeaways
- The Supreme Court sided with Hikma in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., reversing a lower court that had found Hikma liable for inducing patent infringement based on its marketing statements.
- The ruling removes a major legal threat for generic companies using skinny labels to launch on unpatented indications, reducing the risk of costly damages and automatic 30-month litigation stays.
- Brand-name drugmakers may face accelerated generic competition for multi-indication drugs, while legal and commercial teams should reassess labeling and launch strategies in light of the Court's reasoning.
What happened in the Hikma v Amarin case?
On June 4, 2025, the Supreme Court issued a unanimous opinion in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., ruling that Hikma's generic version of Vascepa did not infringe Amarin's patents covering the drug's cardiovascular indication. The Court reversed a Federal Circuit decision that had found Hikma liable for inducing infringement, according to the Supreme Court opinion.
The lower court had determined that Hikma actively induced others to infringe Amarin's CV-indication patents based on the totality of Hikma's statements across the skinny label. The Supreme Court rejected that standard, narrowing the circumstances under which marketing communications can support an inducement finding. The case centered on Hikma's skinny-label approval, which carved out Vascepa's patented cardiovascular indication to allow early entry on unpatented uses.
Why this ruling matters for generic drugmakers
Skinny labels, authorized under the Hatch-Waxman Act, allow generics to enter the market on unpatented indications without being subject to infringement lawsuits and an automatic 30-month stay, according to analysis in the Wisconsin Law Review. The mechanism traces back to the law's goal of balancing generic competition with patent protection — the skinny label would allow Teva to start its generic manufacture while one or more of GSK's method-of-use patents was still in effect, as the National Library of Medicine noted in a review of the legislative history.
Until Thursday, that pathway carried real legal risk. The Federal Circuit had held that a drug manufacturer may sometimes be liable for inducing patent infringement when marketing skinny-label drugs, as the Congressional Research Service summarized in a primer on the Hatch-Waxman framework. The Supreme Court's decision in Hikma v Amarin reins in that theory, making it harder for brand-name companies to sue generics over routine marketing activities tied to a carved-out label.
For business development and investment teams, the ruling provides greater certainty for skinny-label strategies across the pipeline. Generic companies can now pursue launches on unpatented indications with less fear that their promotional materials will be retroactively bundled into an inducement claim. Brand-name firms, meanwhile, may need to adjust their patent enforcement playbooks for multi-indication drugs where one or more uses have lost exclusivity.
Legal teams should review marketing and labeling practices to align with the Court's reasoning, particularly the distinction between statements about the drug itself and statements about a patented use. Commercial teams can reassess launch timelines and competitive positioning for products where skinny-label entry was previously considered too risky.
Frequently Asked Questions
What is a skinny label?
A skinny label is an FDA-approved prescribing label for a generic drug that carves out patented indications from the brand drug's label. Under the Hatch-Waxman Act, this allows a generic manufacturer to launch on unpatented uses while the brand's method-of-use patents remain in force on other indications. The generic company cannot promote or market the carved-out indication.
Did the Supreme Court rule that skinny labels are always legal?
No. The Court ruled that Hikma's specific marketing statements did not induce infringement under the legal standard applied in Hikma v Amarin. The opinion narrows the circumstances in which a brand company can win an inducement case based on a generic's promotional activities, but it does not grant blanket immunity. Generics still cannot actively promote a patented indication, and drug manufacturers may still sometimes be liable for inducing infringement when marketing skinny-label drugs, as the Congressional Research Service has noted.
What does this decision mean for future generic launches?
Generic drugmakers face reduced legal risk when using skinny labels to enter markets on unpatented indications. The ruling lowers the threat of costly infringement lawsuits and preserves skinny labels as a viable route for early market entry. Brand-name companies, particularly those with drugs approved for multiple indications, may see increased generic competition sooner than expected. Deal teams should factor this legal shift into valuations of products approaching patent cliffs on secondary indications.
This article was updated on June 4, 2025, to reflect the Supreme Court's decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Related coverage
Stay Updated on Pharma News
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
